Compare HNRG & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HNRG | SLN |
|---|---|---|
| Founded | 1949 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 743.5M | 678.0M |
| IPO Year | 1995 | 2010 |
| Metric | HNRG | SLN |
|---|---|---|
| Price | $16.73 | $13.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | $25.38 | ★ $42.60 |
| AVG Volume (30 Days) | 831.0K | ★ 1.6M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 116.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $469,466,000.00 | $559,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.12 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 16.09 | N/A |
| 52 Week Low | $13.65 | $4.19 |
| 52 Week High | $24.70 | $17.58 |
| Indicator | HNRG | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 56.95 | 57.67 |
| Support Level | $15.22 | $13.01 |
| Resistance Level | $16.80 | $17.58 |
| Average True Range (ATR) | 0.83 | 0.97 |
| MACD | 0.15 | -0.14 |
| Stochastic Oscillator | 91.97 | 10.95 |
Hallador Energy Co is a vertically integrated, independent power producer (IPP) and fuel company with operations in Indiana. The Company operates across multiple stages of the energy value chain, from accredited capacity and energy to coal. The Company's electric operations are located within the Midcontinent Independent System Operator's (MISO) footprint. The company's business is organized based on the services and products it provide in two segments: (i) Electric Operations and (ii) Coal Operations.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.